Muscular Dystrophy Association Launches Holiday Retail Campaign in Thousands of Retail Locations Nationwide
01 nov. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched its largest Holiday Retail Campaign to fundraise in thousands of retail locations nationwide from...
Muscular Dystrophy Association Announces Collaboration with Mitsubishi Tanabe Pharma America for Remote Digital Technology Research Study for Amyotrophic Lateral Sclerosis (ALS)
30 oct. 2023 09h01 HE
|
Muscular Dystrophy Association
New York, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) and Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced their collaboration for a remote observational...
Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA
26 oct. 2023 16h24 HE
|
Muscular Dystrophy Association
New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique...
Muscular Dystrophy Association Celebrates FDA Approval of ZILBRYSQ® zilucoplan for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients
18 oct. 2023 14h36 HE
|
Muscular Dystrophy Association
New York, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of ZILBRYSQ® zilucoplan for the treatment of...
Muscular Dystrophy Association Celebrates FDA Approval of Amicus Therapeutics’ Pombiliti + Opfolda for Treatment of Pompe Disease
28 sept. 2023 17h00 HE
|
Muscular Dystrophy Association
New York, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of Pombiliti™ (cipaglucosidase alfa-atga) +...
Muscular Dystrophy Association Announces Research Grants Totaling $8.4 Million
13 sept. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the awarding of 37 new grants with a total funding commitment of $8.4 million toward...
Muscular Dystrophy Association Kicks Off 30 Days of Strength Campaign for National Muscular Dystrophy Awareness Month in September
28 août 2023 09h00 HE
|
Muscular Dystrophy Association
New York, Aug. 28, 2023 (GLOBE NEWSWIRE) -- September marks the Muscular Dystrophy Association’s (MDA) kick-off of "National Muscular Dystrophy Awareness Month," to raise awareness and critical...
Muscular Dystrophy Association International Association of Fire Fighters Launch 420 Fill the Boot Fundraisers in Cities Across America Labor Day Weekend for the Muscular Dystrophy Association
21 août 2023 13h01 HE
|
Muscular Dystrophy Association
New York, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) in partnership with the International Association of Fire Fighters (IAFF) today kick off more than 420 Fill the...
Registration Now Open for 2024 MDA Clinical & Scientific Conference, to Showcase Cutting Edge Research Advancements and Clinical Achievements in Neuromuscular Disease
09 août 2023 10h35 HE
|
Muscular Dystrophy Association
New York, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), convener of the largest worldwide gathering of the neuromuscular disease community, announced today that...
Muscular Dystrophy Association Celebrates FDA Approval of UCB’s RYSTIGGO for the Treatment of Generalized Myasthenia Gravis
27 juin 2023 17h18 HE
|
Muscular Dystrophy Association
New York, June 27, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of RYSTIGGO (rozanolixizumab-noli) for the...